DNA Biomed Solns (DNA) — Strategic Asset Allocation Index

Latest as of June 2019: 133.7%

DNA Biomed Solns (DNA) has a Strategic Asset Allocation Index of 133.7% as of June 2019. Strategic assets (PP&E of ILA- plus long-term investments of ILA51.99 Million) total ILA51.99 Million, measured against net assets of ILA38.87 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.

SAAI

133.7%
Strategic Assets / Net Assets

Strategic Assets

ILA51.99 Million
PP&E + LT Investments

PP&E

ILA-
ILA

Net Assets

ILA38.87 Million
ILA

DNA Biomed Solns Strategic Asset Allocation Index (2005–2018)

This chart shows how DNA Biomed Solns's Strategic Asset Allocation Index has evolved across 6 annual periods from 2005 to 2018. As of June 2019, the index stands at 133.7%, representing strategic assets of ILA51.99 Million against net assets of ILA38.87 Million ILA. Explore cash efficiency ratio of DNA Biomed Solns to assess how effectively this company generates cash.

Annual Strategic Asset Allocation Index for DNA Biomed Solns (2005–2018)

The table below presents the year-by-year Strategic Asset Allocation Index for DNA Biomed Solns from 2005 to 2018, covering 6 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see DNA market cap overview.

Year SAAI Strategic Assets (ILA) PP&E LT Investments Net Assets Change (pp)
2018 123.6% ILA80.20 Million ILA- ILA80.20 Million ILA64.90 Million ▲ +12.9 pp
2017 110.7% ILA76.49 Million ILA- ILA76.49 Million ILA69.11 Million ▲ +60.8 pp
2013 49.9% ILA5.74 Million ILA99.00K ILA5.64 Million ILA11.49 Million ▲ +49.8 pp
2012 0.2% ILA18.00K ILA18.00K ILA- ILA11.53 Million ▼ 0.0 pp
2011 0.2% ILA18.00K ILA18.00K ILA- ILA10.45 Million ▼ -28.4 pp
2005 28.6% ILA931.00K ILA931.00K ILA- ILA3.26 Million
pp = percentage points